全文获取类型
收费全文 | 135753篇 |
免费 | 10269篇 |
国内免费 | 244篇 |
专业分类
耳鼻咽喉 | 1269篇 |
儿科学 | 3771篇 |
妇产科学 | 2870篇 |
基础医学 | 20889篇 |
口腔科学 | 3456篇 |
临床医学 | 11819篇 |
内科学 | 27622篇 |
皮肤病学 | 2291篇 |
神经病学 | 13066篇 |
特种医学 | 5568篇 |
外国民族医学 | 10篇 |
外科学 | 17647篇 |
综合类 | 630篇 |
现状与发展 | 1篇 |
一般理论 | 117篇 |
预防医学 | 15220篇 |
眼科学 | 2162篇 |
药学 | 7926篇 |
中国医学 | 244篇 |
肿瘤学 | 9688篇 |
出版年
2023年 | 602篇 |
2022年 | 493篇 |
2021年 | 2444篇 |
2020年 | 1687篇 |
2019年 | 2452篇 |
2018年 | 3041篇 |
2017年 | 2532篇 |
2016年 | 2727篇 |
2015年 | 3097篇 |
2014年 | 4242篇 |
2013年 | 5396篇 |
2012年 | 8373篇 |
2011年 | 8493篇 |
2010年 | 4378篇 |
2009年 | 4443篇 |
2008年 | 7339篇 |
2007年 | 7505篇 |
2006年 | 7232篇 |
2005年 | 6815篇 |
2004年 | 5789篇 |
2003年 | 5476篇 |
2002年 | 4966篇 |
2001年 | 4497篇 |
2000年 | 4423篇 |
1999年 | 3958篇 |
1998年 | 1648篇 |
1997年 | 1357篇 |
1996年 | 1288篇 |
1995年 | 1150篇 |
1994年 | 1075篇 |
1993年 | 994篇 |
1992年 | 2706篇 |
1991年 | 2430篇 |
1990年 | 2302篇 |
1989年 | 2153篇 |
1988年 | 1967篇 |
1987年 | 1715篇 |
1986年 | 1628篇 |
1985年 | 1568篇 |
1984年 | 1142篇 |
1983年 | 979篇 |
1982年 | 540篇 |
1981年 | 468篇 |
1980年 | 410篇 |
1979年 | 871篇 |
1978年 | 530篇 |
1977年 | 437篇 |
1974年 | 426篇 |
1973年 | 418篇 |
1972年 | 369篇 |
排序方式: 共有10000条查询结果,搜索用时 217 毫秒
1.
2.
3.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
4.
5.
6.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
7.
8.
9.
10.